Johnson & Johnson Falls 2.7% as 3.6% MedTech Growth Undercuts Raised Outlook
Updated
Updated · Trefis · Jul 16
Johnson & Johnson Falls 2.7% as 3.6% MedTech Growth Undercuts Raised Outlook
3 articles · Updated · Trefis · Jul 16
Summary
Johnson & Johnson shares fell 2.7% after investors looked past an earnings beat and higher full-year guidance to a weaker-than-expected MedTech performance.
MedTech operational sales rose just 3.6%, with the Abiomed heart-pump business down 2% and electrophysiology growth slowing to 3.1%—a setback in a division meant to provide steady diversification.
That weakness contrasted with stronger pharma results: overall operational sales grew 5.6%, while TREMFYA sales jumped 71% and DARZALEX grew nearly 18% to more than $4 billion.
Management lifted its 2026 operational sales growth forecast to 6.5%-7.1%, but the market read the increase as increasingly dependent on pharma offsetting softer MedTech demand.
The selloff leaves J&J's two-engine growth case under pressure, with investors now focused on whether MedTech—especially cardiovascular—can regain momentum.